May 12, 2021 -- Nuclera has acquired E Ink's microfluidics unit, and, together, they have developed a desktop bioprinter that will be commercially available in 2022.
The microfluidics unit will be part of the newly formed U.S. subsidiary of Nuclera. Under the deal, E Ink will contribute intellectual property, equipment, and assistance from scientists and engineers and will be made the largest stakeholder in Nuclera.
The companies have been working together to create a bioprinter since 2018. E Ink's digital microfluidics has been combined with Nuclera's biopolymer synthesis technology to create lab-on-chip technology that allows users to digitally program bioprinting of proteins and genes on a desktop for next-day production.
The company expects to commercialize the product in 2022.